Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207430 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL1782216 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL8353685 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL13305759 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL5207425 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL7876562 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL7872099 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL24113374 | 0.99 | HSD17B10 (0.45) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL25362467 | 0.99 | HSD17B10 (0.45) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL3700523 | 0.93 | HSD17B10 (0.45) | HSD17B10NR1H2ELANESMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-116096714-A | Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections | 安力高医药股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-102206247-B | Novel peptides as NS3/NS4a serine protease inhibitors of hepatitis C virus | DENDREON CORP | 2013-03-27 | — | — | CN | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| CN-102372764-A | Novel peptides as NS3-serine protease inhibitors of hepatitis c virus | SCHERING CORP | 2012-03-14 | — | — | CN | disclosed |
| CN-102206247-A | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON CORP | 2011-10-05 | — | — | CN | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| CN-101792483-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | SCHERING CORP | 2010-08-04 | — | — | CN | disclosed |
| EP-1481000-B1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-1481000-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| CN-1498224-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | ���鹫˾ | 2004-05-19 | — | — | CN | disclosed |
| EP-1389200-A1 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | disclosed |
| EP-1385870-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | Schering Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030216325-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SAKSENA ANIL K | 2003-11-20 | — | — | US | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002074761-A1 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002008244-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-0053902-B1 | PHOSPHINYLALKANOYL SUBSTITUTED PROLINES | E.R. Squibb & Sons, Inc. (US) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216325-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HSD17B10 1968/4885NR1H2 2620/4885ELANE 109/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | HSD17B10 1968/4885NR1H2 2620/4885ELANE 109/4885 |
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ICAM1 | HSD17B10 3819/4885NR1H2 1321/4885ELANE 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.